Research that is free to access for all investors. Companies commission these providers to write research about them.
Brokers who write research on their corporate clients and make it available through our main bundle offering.
Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.
Event in Progress:
Research Tree provides access to ongoing research coverage, media content and regulatory news on SOPHIRIS BIO. We currently have 0 research reports from 0 professional analysts.
Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield and its partner, Viatris, have increased physician awareness of the differentiating characteristics of Accrufer® as an oral ID drug, in order to ramp up prescriptions (Rxs) and generate sales traction. Positive Rx momentum in 2022 and 2023, is expected to accelerate in 2024 and 2025 with the r
Companies: Shield Therapeutics Plc
Hardman & Co
Companies: IGP RUA BOOM
Cavendish
New management has revitalised Avon. First half earnings were positive across-the-board and slightly ahead of our expectations.
Companies: Avon Protection PLC
Zeus Capital
RUA Life Sciences, through its operating companies, is the rights holder to the novel bio-compatible polymer, Elast-Eon, provides third-party medical device development and manufacturing services and is internally developing Elast-Eon based medical devices to treat cardiovascular conditions. Financially, the company combines established recurring revenue streams with significant upside potential from its pipeline products. We believe the structure and financial opportunities RUA is targeting mak
Companies: RUA Life Sciences Plc
As previously disclosed, Diaceutics delivered revenue of £23.7m for FY23, up 22% YoY (+19% in constant currency) and ended the year with £16.7m in cash and net cash. The reported net loss of £1.7m was in line with our forecast. This was the first year of executing the accelerated growth strategy which was reflected in the growth in revenue, the transition to a higher proportion of recurring revenue driven by adoption of the enhanced DXRX platform while an expanded and reorganised marketing struc
Companies: Diaceutics Plc
Capital Access Group
Three new Pharma Services agreements with large cap pharma in 2024 demonstrate that ANGLE’s business development activities are successfully translating into customer income. These deals will make a valuable contribution to near-term revenues and also have the potential for more sizeable future revenues. Successful development of the underlying Parsortix-based assays could mean a transition into longer-term contracts for larger later-stage clinical studies, perhaps ultimately becoming companion
Companies: ANGLE plc
Trinity Delta
Companies: RUA BOIL TRIN CHAR PPCGF NMT
Evgen Pharma has acquired Chronos Therapeutics Ltd for a total upfront consideration of c£0.9m, payable in Evgen shares. Accompanying this, Evgen has conditionally raised gross proceeds of £0.85m through an equity placing with the potential to raise a further £1.0m through a retail open offer and additionally up to £2.0m. The proceeds will fund several initiatives including maintenance of the acquired Chronos Therapeutics patent portfolio and to continue support manufacturing for lead clinical a
Companies: TheraCryf PLC
Companies: Oxford BioDynamics PLC
Shore Capital
RUA Life Sciences is developing products targeting billion-dollar global healthcare markets, which, if successfully commercialised it will generate significant value for the company. The current raise will support the business as it seeks to deliver the growth opportunities within its Contract Manufacturing business unit and commercialise and partner its lead vascular graft products and its heart valve leaflet composite material. We believe the company offers an attractive combination of establi
Companies: CMH RUA IQG SBTX
Dish of the day Joiners: No joiners today. Leavers: Ergomed has left AIM. What’s cooking in the IPO kitchen?** 9 November: Chapel Down Group ITF: England's leading and largest wine producer with an award-winning range of sparkling and still wines, under the Chapel Down brand. The Company owns, leases and sources from 1,023 acres of vineyards in South East England announces its Admission to AIM after its transfer from the Aquis Apex market. The Company will not be raising new capital or providing
Companies: TXG RQIH TXG SCE MIN AEO KOD ADME ZIN G4M
Hybridan
The Q3 results were in line with the consensus and AV’s estimates and, given the strong momentum across the key focus areas, the management upgraded its 2023 guidance. Moreover, the licensing by Astra of an early-stage obesity drug candidate should be a good addition to the firm’s pipeline, given the huge expansion potential for weight-loss drugs. Overall, a healthily-growing young oncology portfolio, promising prospects in other key areas, a strong pipeline and an improving balance sheet all su
Companies: AstraZeneca PLC
AlphaValue
FAB is a specialised Contract Research Organisation operating in monoclonal antibody engineering and production and supply. The company generated a 79% increase in FY20 revenues driven by its core expertise in antibody humanisation services, successful business development initiatives, with the newly launched RAMPTM technology attracting industry attention and initial revenues. Trading remains resilient to pandemic uncertainty in the year to-date and we leave forecasts unchanged. Development of
Companies: Fusion Antibodies Plc
Allenby Capital
In light of the Brexit vote, we reflect upon the implications for the NHS and the wider healthcare industry. We take a pragmatic approach to how the referendum result will affect staffing, recruitment, clinical trials, drug pricing and small company grant funding in the coming months and years.
Companies: RUA SNG TSTL CNSL SDI BVXP
Share: